Company intelligence / Profile preview

Quris

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Quris has demonstrated proof-of-concept for its AI-driven 'Patients-on-a-Chip' drug safety prediction technology and is collaborating with pharma and academic institutions such as Merck KGaA and the New York Stem Cell Foundation to validate predictions against clinical and genomic data, focusing initially on rare diseases including Fragile X syndrome. Clinical results in humans not yet reported; the platform is used at the pre-clinical/validation stage to improve safety prediction before clinical trials.

Therapeutic areas: OtherNeurologyRare Diseases
Modalities: Small moleculeBiologicGene therapyCell therapy
Industry: Drug Discovery Services

Partnerships

Merck KGaANew York Stem Cell Foundation Research Institute

Beyond the preview

Go deeper on Quris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quris.

Explore the full profile